Concurrent Androgen Deprivation Therapy for Prostate Cancer Improves Survival for Synchronous or Metachronous Non-Small Cell Lung Cancer: A SEER-Medicare Database Analysis.

ABSTRACT:

Introduction

The crosstalk between receptor kinase signaling, such as EGFR and androgen receptor signaling, suggests a potential interaction between androgen deprivation therapy (ADT) and lung cancer outcome.

Methods

We employed the SEER-Medicare data of lung cancer patients diagnosed between 1988 and 2005 to test for an association between ADT for prostate cancer and lung cancer outcome. We employed the Kaplan-Meier method and Cox proportional hazard with log-rank test model to assess any significant impact of ADT on survival.

Results

We included data from 367,750 lung cancer patients; 17.4%, 2.9%, 33.6% and 46.1% with stages I, II, III and IV, respectively; 84.5% were >65 years; 57.2% males; 84.2% Caucasians and 9.3% Blacks. There were 11,061 patients (3%) with a

SUBMITTER: Nazha B 

PROVIDER: S-EPMC9265064 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature